左旋多巴研究的新进展
这是我在Medical News Today上发现的一篇文章，跟大家分享，译得不对的地方，请指正。
Progress In The Development Of New Parkinson’s Drugs
Main Category: Parkinson’s Disease
Also Included In: Neurology / Neuroscience
Article Date: 22 Oct 2010 - 4:00 PDT
帕金森药物研究的新进展
2010年10月22日
The side effects of the standard medication for Parkinson’s disease have long been a preoccupation of brain researchers.
帕金森病的标准治疗所产生的负作用，长期以来令脑研究者们感到头痛。
Now Daniella Rylander has presented new findings in a recently defended PhD thesis at Lund University that provide hope of more effective medication for those who suffer from the nerve cell disease.
朗德大学的丹列拉•雷兰德在最近的博士论文答辩中报告了新的发现，为那些遭受神经细胞疾病折磨的患者提供了更有效治疗的希望。
In her thesis, neuroscience researcher Daniella Rylander presents two important findings that tackle different stages in the development of the uncontrollable jerky movements known as dyskinesia, which are an undesirable effect of treatment with the standard drug levodopa.
在论文中，神经科学研究者丹列拉•雷兰德报告了两项重要的发现，用于处理名为异动症的不可控的忽动忽停的运动过程中的不同阶段，这是使用标准药物左旋多巴治疗时出现的一种讨厌的负作用。
Dr Rylander has studied two different systems in the brain that are believed to play an important role in the development of the side effects glutamate and serotonin. An overactivation of glutamate signals, caused by treatment with levodopa, probably contributes to the development of dyskinesia. Daniella Rylander’s research focuses on blocking this undesirable overactivation.
雷兰德博士对大脑的两个不同系统进行了研究，发现谷氨酸和血清素在引发负作用的过程中起到了重要的作用。左旋多巴治疗所引起的谷氨酸表达的过于活跃，可能是异动症出现的原因。丹列拉•雷兰德的研究集中在阻断这种讨厌的过于活跃。
"The receptor cells have different receptors on their surface where the glutamate is taken in to activate the cell. It is these receptors that I have tried to block. If we could find the right channel and subdue it then we could get more effective treatment with levodopa without any side effects. This has always been my goal", says Daniella Rylander.
“受体细胞在表层上有不同的受体，吸入谷氨酸使细胞活跃起来。我想要阻断的正是这些受体。如果我们能够找到正确的途径并将它制服，那么我们就可以使用没有任何负作用的左旋多巴，从而得到更有效的治疗。这一直是我的目标。”丹列拉•雷兰德说。
Tests in animal models, including rats, have shown very good results for the new method. A drug that blocks glutamate overactivation via the glutamate receptor ’mGluR5’ was used in the study. This has previously been tested on humans and so provides a head start in the time-consuming clinical trials required before a new drug can be introduced.
动物模型实验，包括白鼠，为新的治疗方法显示了非常好的结果。一种通过谷氨酸受体’mGluR5’阻断谷氨酸过于活跃的药物正在研究中使用。这种药物先前曾经对人进行过实验，因而在一种新药被引入前所要求的耗时的临床试验中具有起步前的优势。
Serotonin also plays an important role in the development of dyskinesia in Parkinson’s disease.
血清素对帕金森病中出现的异动症也扮演了重要的角色。
"We have now shown for the first time that individuals who have a particularly large amount of a certain type of fibre on their serotonin cells are also at greater risk of being affected by dyskinesia after levodopa treatment", says Daniella Rylander.
“我们现在第一次证实，那些在血清素细胞中含有特大量纤维类的个体，也将冒左旋多巴治疗后产生异动症的更大风险。”丹列拉•雷兰德说。
The new finding of a clear pathological change in the serotonin system can now be utilised to better tailor the individual treatment of patients with Parkinson’s disease.
对血清素系统中这一明显的病理变化的新发现，现在被用来更好地满足帕金森病人个性化治疗的需要。
Daniella Rylander, who is part of the Basal Ganglia Pathophysiology Unit research group, defended her PhD thesis on 17 September 2010. The thesis is entitled Involvement of non-dopaminergic systems in L-DOPA-induced dyskinesia.
丹列拉•雷兰德，巴塞尔干尼拉病理生理学联合研究小组的成员，于２０１０年９月１７日进行了博士论文答辩，这篇论文的标题是：在左旋多巴引起的异动症中导入非多巴胺能系统。
Sources: Lund University, AlphaGalileo Foundation.
